Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study

Background It is reported that treatment of palmoplantar pustulosis (PPP) with guselkumab has greater improvement in clinical responses terms area severity index (PPPASI) score. Here, we present the effect (100 and 200 mg) on PPP-related serum proteins their association responses. Objectives To analyze effects circulating up to Week 72 evaluate Methods Serum cytokines (interleukin [IL]-17A, IL-17F, IL-22, tumour necrosis factor-alpha, interferon-gamma) 184 inflammation/immune activation-related were evaluated. Baseline cytokine levels for patients PPP compared healthy controls (HCs) detect differentially expressed using Welch's t-test. Correlation individual PPPASI scores was assessed explore associations disease severity. Guselkumab treatment-associated pharmacodynamic (PD) evaluated as fold changes baseline. Results IL-17A, IL-17F IL-22 elevated (n = 159) HCs 25) significantly correlated baseline scores. reduced following treatment, maximal reduction at both doses (all p < 0.01). Lower associated 72. Olink platform analysis identified a decrease chemokine ligand-19 IL-6 placebo. However, difference between groups not significant. The biomarker 100 versus mg comparable, suggesting PD plateaued higher than unlikely increase changes. Conclusions Targeting IL-23 led progressive serum, lower these Th17/Th22 better response after treatment. Clinical Trials.gov identifier NCT02641730.